Industry status analysis
After the glory of the late 1990s, the pharmaceutical intermediate industry has basically entered a mature stage. The competition between enterprises has reached a white hot, and they are fighting for the remaining strength. Whoever can adhere to it is the survivor. At the same time, tempted by various legends and other factors, new investors continue to enter the industry with the dream of "gold rush". However, with the rise of GMP certification required by the state for pharmaceutical enterprises and various overseas certification, the investment scale of the pharmaceutical industry has increased exponentially. How to make limited funds and energy produce economic and social benefits has become the goal of every pharmaceutical intermediate investor.
Track from medicine to medicine
The impact of the process of economic globalization on China's economy is more far-reaching than its concept, that is, each production enterprise does not need to be large and comprehensive, and should focus on its own industries and fields. Other supporting materials and conditions can be completed by social cooperation. Through the formation of a product chain, the two sides can achieve win-win results. Under the influence of this concept, the pharmaceutical industry will transfer the processing of some primary products, such as solvent recovery, to cooperative enterprises for completion. Later, some products with certain pollution and danger were gradually transferred to chemical plants for production, such as phenylacetic acid and chloroacetic acid used in the production of penicillin. A large number of small township enterprises and individual enterprises supporting the production of phenylacetic acid and chloroacetic acid for North China Pharmaceutical have appeared near Shijiazhuang since the 1970s and 1980s.
As the cooperation between the two sides continues to deepen, pharmaceutical enterprises gradually transfer some products with high added value and difficult technology to chemical plants, The production of products such as aminothiaoxime acid AE active ester triazine cyclotetrazolium acetic acid p-hydroxyphenylglycine (potassium Deng salt) ho-epcp used in the production of cephalosporin antibiotics made the branch industry develop rapidly in the 1990s and achieved a number of pharmaceutical intermediate enterprises with an output value of tens of millions to billions of yuan. At present, the industry has developed into a stage of closer cooperation with pharmaceutical enterprises. The manufacturers of pharmaceutical intermediates directly synthesize APIs (fungal powder), and sell the products in the form of chemical products to pharmaceutical enterprises for refining, and then sell them as drugs. The pharmaceutical intermediates industry can further extend the product chain, increase the profits of products and improve the stability of sales. Pharmaceutical enterprises, Reduced investment and put limited funds and energy into aseptic packaging, which they are good at. Because of the pharmaceutical intermediate industry, it is impossible to compete with pharmaceutical enterprises for the market without the production license of pharmaceutical products, so the cooperation between the two sides is complementary.
Basic conditions are still restricting development
In recent years, the rapid development of pharmaceutical intermediates industry has caused many investors' salivation. Enterprises producing pharmaceutical intermediates and APIs have sprung up all over the country. But at the same time, it was eliminated at a similar speed. Many technicians engaged in the development of pharmaceutical intermediates have also intervened in the industry in various forms. However, with the collapse of the corresponding enterprises, they have also returned. The development of this industry seems to be rising and falling like a tide, taking away the hurried back of many losers. The author, as one of many losers. After calm reflection, I think that the reason why many human and financial resources involved in the industry are so "in a hurry" is not that the industry has developed to meet new bottlenecks, but mainly because it is basically but often forgotten by many "gold miners".
With capital and technology, products can be produced. However, reproduction can be carried out only after the products are sold and the funds are recovered in time. Due to the close relationship between the pharmaceutical intermediate industry and the pharmaceutical industry, the sales of products, It is also very subtle. The competition between suppliers has been transformed into the competition of comprehensive strength among enterprises. The specific contents include: intuitive factory appearance, production workshop and laboratory equipment, product packaging and quality, intangible technical force, after-sales service, corporate culture, business philosophy, etc. Therefore, a comprehensive market background is also one of the indispensable conditions.
Bester biotechnology is a trusted developer of pharmaceutical intermediates, specialty APIs, plant extracts, etc. Set up R & D centers and GMP pilot workshops, integrate with universities and colleges, and accelerate the commercialization of production and research. It has the certification certificate issued by the mainstream national regulatory agencies that domestic peer enterprises do not have, as well as the company's own strict management and control system for R & D, production and quality in accordance with strict regulatory provisions. In addition to domestic related enterprises, our products are also exported to Singapore, India, the United States and the European Union. Diversified business directions, boosting the development path of bester biotechnology.